Long-Term Follow-up of Thyroid Nodule Growth

 

 Buy Article Permissions and Reprints

Summary

Benign thyroid nodules are common in iodine deficient countries. Although many recent studies have addressed the molecular basis and short-term outcome of treatment in nodular thyroid disease, data on the long-term follow-up of thyroid nodule growth are widely lacking. The aim of the present study was to evaluate the long-term behaviour of benign thyroid nodules growth.

We followed 109 consecutive patients seen at yearly intervals in our Outpatient Clinic for at least 3 years (range 3-12 years, mean 4.9 ± 2.6 years) presenting with 139 benign nodules in uni- or multinodular goiters. The size of the nodules and thyroid glands was analysed retrospectively. The study included a spectrum of benign thyroid nodules, 86 functioning and 53 non-functioning. 27 patients were treated with levothyroxine, 8 with iodide and 16 with a combination of both. 58 patients were not treated mainly because of thyroid functional autonomy. Patients with overt hyperthyroidism or suspected malignancy by fine-needle aspiration were excluded from the study. The nodules and glands were assessed by ultrasonography at yearly intervals and documented by photoprints. Relevant growth was defined as an increase in nodule volume of at least 30%. For statistical analyses, Cox Proportional Hazard Model and life-table analyses according to Kaplan-Meier were performed. Most thyroid nodules grew slowly but continously during follow-up. After about 3 years, half of the nodules had increased their volume by at least 30%. Growth of the nodules was significantly faster than of the corresponding thyroid glands (p < 0.0001).

Age and sex of the patients and size or function of the nodules at initial presentation were not significantly related to their growth. Suppression of TSH did not affect growth of the nodules irrespective of the source of thyroid hormones, endogenous or by administration of levothyroxine. In conclusion, benign thyroid nodules have a slow intrinsic growth potential, which is apparently higher than that of the non-nodular tissue. In this study, not only nodular but even non-nodular goiter growth continues in the majority of patients. Exogeneous factors, including therapy with levothyroxine and/or iodide, appear to have little effect on the growth behaviour.

References

• 1 Bennedbaek F N, Nielsen L K, Hegedus L. Effect of percutaneous ethanol injection therapy versus suppressive doses of L-thyroxine on benign solitary solid cold thyroid nodules: a randomized trial.  J Clin Endocrinol Metabol. 1998;  83 830-835
  CrossrefPubMedGoogle Scholar
• 2 Brix T H, Kyvik K O, Hegedus L. Major role of genes in the etiology of simple goiter in female: a population based twin study.  J Clin Endocrinol Metabol. 1999;  84 3071-3075
  CrossrefPubMedGoogle Scholar
• 3 Brunn J, Block U, Bos U, Kunze W P, Scriba P C. Volumetrie der Schilddrüsenlappen mittels Real-Time-Sonographie.  Dtsch Med Wochenschrift. 1981;  106 1338-1340
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Burgi H, Supersaxo Z, Selz B. Iodine deficiency diseases in Switzerland one hundred years after Theodor Kocher's survey: a historical review with some new goitre prevalence data.  Acta Endocrinol. 1990;  123 577-590
  PubMedGoogle Scholar
• 5 Celani M F, Mariani M, Mariani G. On the usefulness of levothyroxine suppressive therapy in the medical treatment of benign solitary, solid or predominantly solid thyroid nodules.  Acta Endocrinol. 1990;  123 603-608
  PubMedGoogle Scholar
• 6 Cheung P S, Lee J M, Boey J H. Thyroxine suppressive therapy of benign solitary thyroid nodules: a prospective randomized study.  World J Surg. 1989;  13 818-822
  CrossrefPubMedGoogle Scholar
• 7 Csako G, Byrd D, Wesley R A, Sarlis N J, Skarulis M C, Nieman L K, Pucino F. Assessing the effects of thyroid suppression on benign solitary thyroid nodules. A model for using quantitative research synthesis.  Medicine. 2000;  79 9-26
  CrossrefPubMedGoogle Scholar
• 8 Delange F. The disorders induced by iodine deficiency.  Thyroid. 1994;  4 107-128
  CrossrefPubMedGoogle Scholar
• 9 Derwahl M. Molekulare Aspekte in der Pathogenese von Knoten und Adenomen der Schilddrüse.  Schweiz Med Wochenschrift. 1994;  124 1613-1618
  PubMedGoogle Scholar
• 10 Derwahl M, Broecker M, Kraiem Z. Clinical Review 101: Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors.  J Clin Endocrinol Metab. 1999;  84 829-834
  CrossrefPubMedGoogle Scholar
• 11 Dunn J T, Medeiros-Neto G A. Endemic goiter and cretinism: Continuing threats to the world health. Pan American Health Organization, WHO, Scientific Publication No. 292 1974
  Google Scholar
• 12 Gharib H, James E M, Charboneau J W, Naessens J M, Offord K P, Gorman C A. Suppressive therapy with levothyroxine for solitary thyroid nodules: A double-blind controlled clinical study.  N Engl J Med. 1987;  317 70-75
  CrossrefPubMedGoogle Scholar
• 13 Gharib H. Changing concepts in the diagnosis and managment of thyroid nodules.  Endocrinol Metab Clin North Am. 1997;  26 777-800
  CrossrefPubMedGoogle Scholar
• 14 Gharib H, Mazzaferri E L. Thyroxine suppressive therapy in patients with nodular thyroid disease.  Ann Intern Med. 1998;  128 386-39
  PubMedGoogle Scholar
• 15 Gullu S, Gursus M A, Baskal N, Uysal A R, Kamel A N, Erdogan G. Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter.  Endocr J. 1999;  46 221-226
  PubMedGoogle Scholar
• 16 Gutekunst R, Smolarek H, Hasenpusch U, Stubbe P, Friedrich H J, Wood W G, Scriba P C. Goitre epidemiology: thyroid volume, iodine excretion, thyroglobulin and thyrotropin in Germany and Sweden.  Acta Endocrinol. 1986;  112 494-501
  PubMedGoogle Scholar
• 17 Hamburger J I, Miller J M, Kini S R. Diagnosis of thyroid nodules by needle biopsy. In: Ingbar SH, Bravermann LE (eds), Werner's the thyroid JB Lippincott Company, Philadelphia 1986: 592-604
  Google Scholar
• 18 Hamburger J I, Hamburger S W. Diagnosis and management of large toxic multinodular goiters.  J Nucl Med. 1985;  26 888-892
  PubMedGoogle Scholar
• 19 Hampel R, Kuhlberg T, Klein K, Jerichow J U, Pichmann E G, Clausen V, Schmidt I. Strumaprävalenz in Deutschland ist größer als bisher angenommen.  Med Klinik. 1995;  90 342-349
  PubMedGoogle Scholar
• 20 Knudsen N, Bols B, Bulow I, Jorgensen T, Perrild H, Ovesen L, Laurberg P. Validation of ultrasonography of the thyroid gland for epidemiological purposes.  Thyroid. 1999;  9 1069-1074
  CrossrefPubMedGoogle Scholar
• 21 Knudsen N, Perrild H, Christiansen E, Rasmussen S, Dige-Petersen H, Jorgensen T. Thyroid structure and size and two-year follow-up of solitary cold thyroid nodules in an unselected population with borderline iodine deficiency.  Eur J Endocrinol. 2000;  142 224-230
  CrossrefPubMedGoogle Scholar
• 22 Kopp P, Kimura E T, Aeschimann S, Oestreicher M, Tobler A, Fey M F, Studer H. Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters.  J Clin Endocrinol Metab. 1994;  79 134-139
  CrossrefPubMedGoogle Scholar
• 23 Kuma K, Matsuzuka F, Kobayashi A, Hirai K, Morita S, Miyauchi A, Katayama S, Sugawara M. Outcome of long standing solitary thyroid nodules.  World J Surg. 1992;  16 583-588
  CrossrefPubMedGoogle Scholar
• 24 Kuma K, Matsuzuka F, Yokozawa T, Miyauchi A, Sugawara M. Fate of untreated benign thyroid nodules: results of long-term follow-up.  World J Surg. 1994;  18 495-499
  CrossrefPubMedGoogle Scholar
• 25 La Rosa G L, Ippolito A M, Lupo L, Cercabene G, Santonocito M G, Vigneri R, Belfiore A. Cold thyroid nodule reduction with L-thyroxine can be predicted by initial nodule volume and cytological characteristics.  J Clin Endocrinol Metab. 1996;  81 4385-4387
  CrossrefPubMedGoogle Scholar
• 26 Lima N, Knobel M, Cavaliere H, Sztejnsznajd C, Tomimori E, Medeiros-Neto G. Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters.  Thyroid. 1997;  7 691-697
  CrossrefPubMedGoogle Scholar
• 27 Mainini E, Martinelli I, Morandi G, Villa S, Stefani I, Mazzi C. Levothyroxine suppressive therapy for solitary thyroid nodule.  J Endocrinol Invest. 1995;  18 797-799
  PubMedGoogle Scholar
• 28 Paggi A, Persegani-Trimarchi C, Russo P, Mastropasqua M, Mosetti M A, Losi T, Leri O. Solitary nodular disease and multinodular goiter: a retrospective study on suppressive versus replacement levothyroxine therapy.  Endocr Res. 1999;  25 229-238
  PubMedGoogle Scholar
• 29 Papini E, Bacci V, Panunzi C, Pacella C M, Fabbrini R, Bizzarri G, Petrucci L, Giammarco V, La Medica P, Masala M. et al . A prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules.  Clin Endocrinol. 1993;  38 507-513
  CrossrefPubMedGoogle Scholar
• 30 Papini E, Petrucci L, Guglielmy R, Panunzi C, Rinaldi R, Bacci V, Crescenci A, Nardi F, Fabbrini R, Pacella C M. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules.  J Clin Endocrinol Metab. 1998;  83 780-783
  CrossrefPubMedGoogle Scholar
• 31 Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G. Somatic mutation in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.  Nature. 1993;  365 649-651
  Google Scholar
• 32 Parma J, Duprez L, Van Sande J, Paschke R, Tonacchera M, Dumont J, Vassart G. Constitutively active receptors as a disease-causing mechanism.  Mol Cell Endocrinol. 1994;  100 159-162
  CrossrefPubMedGoogle Scholar
• 33 Paschke R, Ludgate M. The thyrotropin receptor in thyroid diseases.  N Engl J Med. 1997;  337 1675-1681
  CrossrefPubMedGoogle Scholar
• 34 Peter H J, Gerber H, Studer H, Smeds S. Pathogenesis of heterogenity in human multinodular goiter. A study on growth and function of thyroid tissue transplantated onto nude mice.  J Clin Invest. 1985;  76 1992-2002
  PubMedGoogle Scholar
• 35 Reverter J L, Lucas A, Salinas I, Audi L, Foz M, Sanmarti A. Suppressive therapy with levothyroxine for solitary thyroid nodules.  Clin Endocrinol. 1992;  36 25-28
  CrossrefPubMedGoogle Scholar
• 36 Scriba P C, Beckers. et al . Goitre and iodine deficiency in Europe. Report of the subcommitte for the study of endemic goitre and iodine deficiency of European Thyroid Association.  Lancet. 1289-1293 1985; 
  CrossrefPubMedGoogle Scholar
• 37 Smeds S, Peter J H, Jortso E, Gerber H, Studer H. Naturally occurring clones of cells with high intrinsic proliferation potential within the follicular epitheelium of mouse thyroids.  Cancer Res. 1987;  47 1646-1651
  PubMedGoogle Scholar
• 38 Studer H, Peter H J, Gerber H. Natural heterogeneity of thyroid cells: the basis for understanding thyroid function and nodular goiter growth.  Endocr Rev. 1989;  10 125-135
  PubMedGoogle Scholar
• 39 Studer H, Derwahl M. Mechanisms of nonneoplastic endocrine hyperplasia - a changing concept: a review focused on the thyroid gland.  Endocr Rev. 1995;  16 411-426
  CrossrefPubMedGoogle Scholar
• 40 Tunbridge W M, Evered D C, Hall R, Appleton D, Brewis M, Clark F, Evans J G, Young E, Bird T, Smith P A. The spectrum of thyroid disease in a community: the Whickham survey.  Clin Endocrinol. 1977;  7 481-493
  Google Scholar
• 41 Vanderpump M P, Tunbridge W M, French J M, Appleton D, Bates D, Grimley Evans J, Hasan D M, Rodgers H, Tunbridge F. et al . The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey.  Clin Endocrinol. 1995;  43 55-68
  Google Scholar
• 42 Zelmanovitz F, Genro S, Gross J L. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumultative meta-analysis.  J Clin Endocrinol Metab. 1998;  83 3881-3885
  CrossrefPubMedGoogle Scholar

Dr. B. Quadbeck

Division of Endocrinology

Department of Medicine

University of Essen

Hufelandstr. 55

45122 Essen

Germany

Phone: + 49 201 723 2821

Fax: + 49 201 723 5972

Email: beate.quadbeck@uni-essen.de